Project Grant R37CA302885
Award Date 8/5/25
Completion Date 7/31/30
Dollars Obligated $627K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- This federal Project Grant award of $317,420 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop and validate a patient-ready callascope device for cervical imaging and cancer prevention in low- and middle-income countries (LMICs). The primary focus is on creating point-of-care solutions for screening, diagnosis, and treatment that can be delivered by community health workers and midwives, thereby increasing access to care. Key...
- This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $367,472 to support the development of Gynion, LLC's ClaraBlex gel for the ablative treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection. The ClaraBlex gel, formulated with trichloroacetic acid, is designed to provide a simple, effective, and affordable point-of-care treatment that can be readily...
- Morphogenesis, Inc. was awarded a $1,200,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, to develop a low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the United States. The funding supports optimization of Morphogenesis' IFX-HU2.1 plasmid DNA-based cream formulation for temperature stability using established methods and models. In vitro...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is supporting research to develop a promising low-toxicity therapeutic strategy for cervical cancer. The $376,490 award to the University of Oklahoma Health Sciences Center will investigate combining a C-MYC inhibitor (MYCI975) with the novel investigational agent SHETA2 to target metabolic reprogramming in cervical cancer. Preliminary studies indicate SHETA2 disrupts mitochondrial function and...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to Nanocan Therapeutics Corporation in collaboration with Johns Hopkins University, will fund the development and first clinical trial of an innovative Liquid Immunotherapeutic Fiducial Eluter (LIFE) gel technology. The $998,781 award, with a project period from September 2025 to November 2026, aims to extend the use of local radiotherapy from palliative to potential distant...
- This federal Project Grant award of $295,881 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Osel, Inc., a biotechnology company based in California, aims to develop a novel antimicrobial approach to treat chemoradiation-resistant cervical cancer. The key objective is to synthesize and characterize the potent bacteriocin GASK7B, which selectively inhibits the pathogenic Lactobacillus iners strain that is linked to decreased survival in cervical cancer patients...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $371,161 to develop advanced AI-based risk models for cervical cancer screening in low-resource settings. The project aims to leverage time-series imaging data and self-supervised learning to enhance the diagnostic accuracy of automated visual evaluation (AVE) models. The goal is to create a comprehensive risk stratification system that combines imaging data, HPV...
- This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $442,750.00 to New York University (NYU) to conduct a study on implementation strategies for cervical cancer control policies in Africa. The project aims to: (A) Engage a network of experts from African low- and middle-income countries (LMICs) and global agencies through a Delphi process to identify determinants of policy implementation success, using the Consolidated...
- This Project Grant award from the National Cancer Institute (NCI), under the Federal Assistance Listings program CFDA 93.395 Cancer Treatment Research, provides $406,500.00 to support the development of a novel, low-cost, single-use trans-nasal cryotherapy device for esophageal cancer treatment in low-resource settings. The project aims to design and validate a functional prototype of this first-of-its-kind device, which would enable unsedated cryoablation procedures to be administered through...
- This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research by the University of Texas MD Anderson Cancer Center to develop a Globally Accessible and Pragmatic Predictive Signature (GAPPS) for risk stratification of patients with locally advanced cervical cancer. The $498,565 award is intended to address the need for evidence-based, globally applicable early-treatment biomarkers to optimize radiation...